|
|
||||||||||
|
J Am Coll Cardiol, 2004; 43:1149-1153, doi:10.1016/j.jacc.2003.10.056 © 2004 by the American College of Cardiology Foundation |
* Department of Cardiology, CARE Hospital, Hyderabad, India
Manuscript received July 27, 2003; revised manuscript received September 25, 2003, accepted October 19, 2003.
* Reprint requests and correspondence: Dr. B. K. S. Sastry, Cardiologist, CARE Hospital, Exhibition Road, Nampally, Hyderabad. AP, India 500 001.
bkssastry{at}hotmail.com
OBJECTIVES: In a randomized, double-blind, crossover design, we compared the efficacy of sildenafil with placebo in patients with primary pulmonary hypertension (PPH). The primary end point was the change in exercise time on treadmill using the Naughton protocol. Secondary end points were change in cardiac index and pulmonary artery systolic pressure as assessed by Doppler echocardiography and quality of life (QOL) as assessed by a questionnaire.
BACKGROUND: Primary pulmonary hypertension is a disorder with limited treatment options. Uncontrolled studies had shown sildenafil to be beneficial in the treatment of PPH.
METHODS: After initial clinical evaluation, including Doppler echocardiography and treadmill exercise test, patients were randomized to placebo or sildenafil with dosages ranging from 25 to 100 mg thrice daily on the basis of body weight. The evaluation was repeated after six weeks. Then patients were crossed over to alternate therapy. Final evaluation was performed after another six weeks of treatment.
RESULTS: Twenty-two patients completed the study. Exercise time increased by 44% from 475 ± 168 s at the end of placebo phase to 686 ± 224 s at the end of sildenafil phase (p < 0.0001). With sildenafil, cardiac index improved from 2.80 ± 0.9 l/m2 to 3.45 ± 1.1 l/m2 (p < 0.0001), whereas pulmonary artery systolic pressure decreased insignificantly from 105.23 ± 17.82 mm Hg to 98.50 ± 24.38 mm Hg. There was significant improvement in the dyspnea and fatigue components of the QOL questionnaire. During the placebo phase, one patient died and another had syncope. There were no serious side effects with sildenafil.
CONCLUSIONS: Sildenafil significantly improves exercise tolerance, cardiac index, and QOL in patients with PPH.
| ||||||||
This article has been cited by other articles:
![]() |
C P Denton, J E Pope, H-H Peter, A Gabrielli, A Boonstra, F H J van den Hoogen, G Riemekasten, S De Vita, A Morganti, M Dolberg, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases Ann Rheum Dis, September 1, 2008; 67(9): 1222 - 1228. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, D. B. Taichman, and R. L. Doyle Health-related Quality of Life and Patient-reported Outcomes in Pulmonary Arterial Hypertension Proceedings of the ATS, July 15, 2008; 5(5): 623 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF] |
||||
![]() |
National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF] |
||||
![]() |
J. M. Wryobeck, G. Lippo, V. McLaughlin, M. Riba, and M. Rubenfire Psychosocial Aspects of Pulmonary Hypertension: A Review Psychosomatics, December 1, 2007; 48(6): 467 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gamboa, D. Robbins, and Z. Saba Bleeding After Circumcision in a Newborn Receiving Sildenafil Clinical Pediatrics, December 1, 2007; 46(9): 842 - 843. [Abstract] [PDF] |
||||
![]() |
G.-P. Diller, K. Dimopoulos, H. Kafka, S. Y. Ho, and M. A. Gatzoulis Model of chronic adaptation: right ventricular function in Eisenmenger syndrome Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H54 - H60. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Poschet, G. S. Timmins, J. L. Taylor-Cousar, W. Ornatowski, J. Fazio, E. Perkett, K. R. Wilson, H. D. Yu, H. R. de Jonge, and V. Deretic Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L712 - L719. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-P. Diller and M. A. Gatzoulis Pulmonary Vascular Disease in Adults With Congenital Heart Disease Circulation, February 27, 2007; 115(8): 1039 - 1050. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. Trow Clinical Year in Review II: Occupational Lung Disease, Pulmonary Vascular Disease, Bronchiectasis, and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 1, 2006; 3(7): 557 - 560. [Full Text] [PDF] |
||||
![]() |
G.-P. Diller, K. Dimopoulos, C. S. Broberg, M. G. Kaya, U. S. Naghotra, A. Uebing, C. Harries, O. Goktekin, J. S. R. Gibbs, and M. A. Gatzoulis Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study Eur. Heart J., July 2, 2006; 27(14): 1737 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-K. Dai, M.-S. Tan, C.-Y. Chai, S.-H. Chou, P.-C. Lin, J.-L. Yeh, A. Y. Jeng, C.-I Chang, I.-J. Chen, and J.-R. Wu Effects of Sildenafil on Pulmonary Hypertension and Levels of ET-1, eNOS, and cGMP in Aorta-Banded Rats. Experimental Biology and Medicine, June 1, 2006; 231(6): 942 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R.V. Castro, I. Verde, D. M.F. Cooper, and R. Fischmeister Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes Circulation, May 9, 2006; 113(18): 2221 - 2228. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Baquero, A. Soliz, F. Neira, M. E. Venegas, and A. Sola Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study Pediatrics, April 1, 2006; 117(4): 1077 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Nahata, R. S. Morosco, and M. T. Brady Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children Am. J. Health Syst. Pharm., February 1, 2006; 63(3): 254 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Pitari, R. I. Baksh, D. M. Harris, P. Li, S. Kazerounian, and S. A. Waldman Interruption of Homologous Desensitization in Cyclic Guanosine 3',5'-Monophosphate Signaling Restores Colon Cancer Cytostasis by Bacterial Enterotoxins Cancer Res., December 1, 2005; 65(23): 11129 - 11135. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Provencher, X. Jais, A. Yaici, O. Sitbon, M. Humbert, and G. Simonneau Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture Chest, December 1, 2005; 128(6_suppl): 622S - 628S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Provencher, X. Jais, A. Yaici, O. Sitbon, M. Humbert, and G. Simonneau Clinical Challenges in Pulmonary Hypertension: Roger S. Mitchell Lecture Chest, December 1, 2005; 128(6_suppl): 622S - 628S. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Galie, H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension N. Engl. J. Med., November 17, 2005; 353(20): 2148 - 2157. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur. Respir. J., November 1, 2005; 26(5): 858 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zaiman, I. Fijalkowska, P. M. Hassoun, and R. M. Tuder One Hundred Years of Research in the Pathogenesis of Pulmonary Hypertension Am. J. Respir. Cell Mol. Biol., November 1, 2005; 33(5): 425 - 431. [Full Text] [PDF] |
||||
![]() |
P. Deruelle, T. R. Grover, and S. H. Abman Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L798 - L806. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fung, R. R. Fiscus, A. P. C. Yim, G. D. Angelini, and A. A. Arifi The Potential Use of Type-5 Phosphodiesterase Inhibitors in Coronary Artery Bypass Graft Surgery Chest, October 1, 2005; 128(4): 3065 - 3073. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Bahadur, V. D. Aggarwal, M. Mali, and A. Thamba Novel therapeutic option in hypertensive crisis: sildenafil augments nitroprusside-induced hypotension Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1254 - 1256. [Full Text] [PDF] |
||||
![]() |
J. Ng, S. J. Finney, R. Shulman, G. J. Bellingan, M. Singer, and P. A. Glynne Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil? Br. J. Anaesth., June 1, 2005; 94(6): 774 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J Lee, T. B Chiao, and M. P Tsang Sildenafil for Pulmonary Hypertension Ann. Pharmacother., May 1, 2005; 39(5): 869 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Deruelle, T. R. Grover, L. Storme, and S. H. Abman Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L727 - L733. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Takimoto, H. C. Champion, D. Belardi, J. Moslehi, M. Mongillo, E. Mergia, D. C. Montrose, T. Isoda, K. Aufiero, M. Zaccolo, et al. cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism Circ. Res., January 7, 2005; 96(1): 100 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Oudiz and K. Wasserman Clinical efficacy of sildenafil in primary pulmonary hypertension J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2256 - 2256. [Full Text] [PDF] |
||||
![]() |
B.K.S. Sastry and C. Narasimhan Reply J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2256 - 2257. [Full Text] [PDF] |
||||
![]() |
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF] |
||||
![]() |
M.M. Hoeper, C. Faulenbach, H. Golpon, J. Winkler, T. Welte, and J. Niedermeyer Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur. Respir. J., December 1, 2004; 24(6): 1007 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436. [Full Text] [PDF] |
||||
![]() |
Other articles noted Evid. Based Med., September 1, 2004; 9(5): e5 - e5. [Full Text] [PDF] |
||||
![]() |
Sildenafil for Primary Pulmonary Hypertension? Journal Watch Cardiology, July 2, 2004; 2004(702): 4 - 4. [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |